PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Res. Author manuscript; available in PMC 2007 October 4.
Published in final edited form as:
PMCID: PMC2000837
NIHMSID: NIHMS27155

A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells

Abstract

The propensity for prostate cancer to metastasize to bone led us and others to propose that bidirectional interactions between prostate cancer cells and bone are critical for the preferential metastasis of prostate cancer to bone. We previously identified a secreted isoform of ErbB3 (p45-sErbB3) in bone marrow supernatant samples from men with prostate cancer and bone metastasis and showed by immunohistochemical analysis of human tissue specimens that p45-sErbB3 was highly expressed in metastatic prostate cancer cells in bone Here we show that p45-sErbB3 stimulated mouse calvaria to secrete factors that increased the invasiveness of prostate cancer cells in a Boyden chamber invasion assay. Using gene array analysis to identify p45-sErbB3–responsive genes, we found that p45-sErbB3 upregulated expression of osteonectin/SPARC, biglycan, and type I collagen in calvaria. We further show that recombinant osteonectin increased the invasiveness of PC-3 cells, whereas osteonectin-neutralizing antibodies blocked this p45-sErbB3–induced invasiveness. These results indicate that p45-sErbB3 enhances the invasiveness of PC-3 cells in part by stimulating the secretion of osteonectin by bone. Thus, p45-sErbB3 may mediate the bidirectional interactions between prostate cancer cells and bone via osteonectin.

Keywords: prostate cancer, bone metastasis, p45-sErbB3, osteonectin, SPARC

Introduction

Prostate cancer is the most common malignancy among men in the United States. Men with advanced prostate cancer often have symptoms attributable to bone metastases, including pain, spinal cord compression, nerve root impingement, and bone marrow failure (1). Autopsy studies of men who died of prostate cancer indicate that 83% of them had evidence of bone metastasis (2). The proclivity of prostate cancer to metastasize to bone is not fully understood, but interactions between the disseminated cancer cells and the bone microenvironment seem to be critical for the process (3, 4).

One explanation for the preferential growth of prostate cancer in bone is the presence of bidirectional interactions in which prostate cancer cells secrete paracrine factors that affect bone and bone in turn releases factors that modulate prostate cancer cell activity (5, 6). In support of this concept are findings that injection of prostate cancer cells in combination with bone stromal cells increased tumorigenicity in vivo (3), and that coculturing prostate cancer cells with osteoblasts in vitro led to increased proliferation of both the osteoblasts and the cancer cells (7), suggesting that bone stromal cells provide factors that enhance prostate cancer progression in bone. Identification of the molecular determinants that mediate such interactions will provide the basis for developing strategies to prevent or treat bone metastases.

Our previous investigation of proteins that participate in prostate cancer bone metastases led to the identification of a soluble form of ErbB3, with a molecular mass of 45 kDa (p45-sErbB3, previously named MDA-BF-1), in pooled bone marrow supernatant samples from men with prostate cancer that had metastasized to bone (8). Subsequent examination of this soluble p45-sErbB3 during prostate cancer progression showed it to be expressed in metastatic prostate cancer cells in lymph nodes and bone but not in prostate cancer cells in the prostate (8). The p45-sErbB3 protein exhibited specific binding to plasma membranes prepared from cells of osteoblastic lineage but not to plasma membranes from PC-3 or HEK293 cells, suggesting that p45-sErbB3 might have specific interactions with osteoblasts (9). Indeed, functional studies showed that p45-sErbB3 promoted the growth and differentiation of osteoblasts both in vitro and in vivo (Lin et al., manuscript submitted). These observations support the hypothesis that p45-sErbB3 is a prostate cancer cell–derived paracrine factor that affects bone homeostasis.

In this study, we found that p45-sErbB3 stimulated calvaria to secrete several extracellular matrix proteins including osteonectin, which in turn enhanced the invasiveness of the prostate cancer cell lines PC-3 and C4-2B. These observations suggest that p45-sErbB3 may be involved in the bidirectional interactions between prostate cancer cells and bone by stimulating the bone to release factors that subsequently facilitate the metastasis of prostate cancer to bone.

Materials and Methods

Cell cultures

The prostate cancer cell lines LNCaP and PC-3 were obtained from American Type Culture Collection (Manassas, VA). C4-2B was kindly provided by Dr. L.W. Chung. These cells were propagated at 37°C with 5% CO2 in complete RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum.

Generation of recombinant p45-sErbB3 and osteonectin

Recombinant adenovirus containing p45-sErbB3 cDNA (GenBank U88358) with a histidine7 tag at the carboxyl terminus was generated and used to infect PC-3 cells. The histidine-tagged p45-sErbB3 was secreted into the cell culture medium, from which it was purified to homogeneity by metal affinity chromatography. Recombinant osteonectin was expressed in insect cells by using baculoviral vector and purified as described previously (10).

Organ culture of mouse calvaria and preparation of conditioned medium

Calvaria of 4-day-old CD1 mice were excised and cut in half along the midline for paired comparisons: one half was cultured in a BGJb medium (Invitrogen) containing 0.1% bovine serum albumin and used as a control, and the other half was cultured in the same medium but with 100 ng/ml of recombinant p45-sErbB3. After 4 days of culture, calvaria were processed for staining with hematoxylin and eosin or for RNA extraction. Conditioned medium was concentrated by using a Centriplus YM-10 (Millipore, Billerica, MA) and used for western blotting and invasion assays.

RNA preparation, gene array analysis and northern blotting

Total RNA was extracted with Trizol (Invitrogen) and was further purified by the use of a Mini-RNA extraction kit (Stratagene). RNAs were used to probe Osteogenesis GEarrays containing skeletal-related genes (SuperArray Bioscience). Raw data were normalized by the GEarray Analyzer software. For northern blotting, hybridization probes for mouse osteonectin, type I collagen, and biglycan were obtained by RT-PCR. Primers for osteonectin were 5′-GATCAGCACCCTATTGATGG-3′ and 5′-TAAGCACAGAGTCTGGGTGA-3′; primers for type I collagen were 5′-TCTGAAGGTCCCCAGGGTGT-3′ and 5′-ACTGCCAGTGAGACCCTTGG-3′; and primers for biglycan were 5′-CCT GAG TTT TCT GCC TAC CC-3′ and 5′-AGGGAGTCTCTGAGTGGACA-3′. A probe for hybridization of mouse 18S ribosome RNA, obtained from Ambion, was used for calibrating the RNA sample on the hybridization membrane.

Western blotting

Proteins from conditioned medium were denatured and separated on 4%–12% acrylamide gels (Invitrogen) by SDS–PAGE and were transferred onto nitrocellulose membranes. Polyclonal anti-osteonectin antibody (H-90, Santa Cruz Biotechnology) was used for immunoblotting.

Invasion assay

The ability of prostate cancer cells to penetrate a synthetic basement membrane was assessed in a Matrigel–Boyden chamber invasion assay (BD Biosciences). In this assay, concentrated conditioned medium or purified recombinant osteonectin was reconstituted in RPMI 1640 and added to the bottom wells. For the antibody neutralization experiments, the conditioned medium in the bottom wells had been preincubated with 1 μg/ml of affinity purified rabbit polyclonal anti-osteonectin antibody, mouse monoclonal anti-osteonectin antibody 293 (11), or normal rabbit or mouse IgG, for 2 hours at room temperature. LNCaP, C4-2b, or PC-3 cells in RPMI 1640 were seeded in the upper chambers and incubated at 37°C for 17–20 h. After the incubation, cells that remained in the chambers were wiped off with cotton swabs, and cells that had reached the other side of the filter membrane were fixed and stained with toluidine blue. Each membrane was subjected to serial photomicroscropy over the entire membrane. Cells were counted with the aid of the NIH Image J program.

Statistical analysis

All data are expressed as means with standard deviations (SD). The statistical significance of differences between two groups was analyzed by Student's t-tests. Differences with P values of less than 0.05 were considered statistically significant.

Results

Conditioned medium from p45-sErbB3-treated calvaria increases the invasiveness of prostate cancer cells

We propose that the osteoblastic character of prostate cancer bone metastases is initiated by osteoblast regulatory factors that increase bone formation; the newly formed bone in turn provides factors that enhance the invasion, survival, or proliferation of the prostate cancer cells in the bone (6). To examine the effect of p45-sErbB3 on bone growth, we used a bone organ culture assay in which paired halves of newborn mouse calvaria were treated or not treated with 100 ng/ml of purified recombinant p45-sErbB3 for 4 days. Calvaria were subsequently processed for histologic analysis and the conditioned medium was collected for protein functional studies (Fig. 1A). We found that the calvaria treated with p45-sErbB3 were thicker than the untreated controls (Fig. 1B). This confirmed our previous observation that p45-sErbB3 leads to increased bone formation (Lin et al., submitted).

Fig. 1
Factors secreted by osteoblasts exposed to p45-sErbB3 enhance the invasiveness of prostate cancer cells. A, experimental plan for examining the effect of p45-sErbB3 on mouse calvaria, both in organ-culture assays and in conditioned medium. B, histologic ...

To investigate the possibility that p45-sErbB3 stimulates the newly formed bone to secrete factors that promote the metastasis or growth of prostate cancer in bone, we examined the effect of conditioned medium from the p45-sErbB3–treated calvaria on the proliferation or invasiveness of LNCaP, C4-2B, and PC-3 cells. The LNCaP cell line was derived from a lymph node metastasis; C4-2B is a LNCaP subline derived from a xenograft bone metastasis; whereas PC-3 was derived from a prostate cancer bone metastasis. The conditioned medium from the p45-sErbB3–treated calvaria had no effect on the proliferation of any of the three cell lines, in comparison with medium from control (untreated) calvaria (data not shown). However, exposure to the same conditioned medium significantly enhanced the invasiveness of the bone-derived PC-3 cells (Fig. 1C, D) and C4-2B cells (Fig. 1D) in a Boyden chamber transwell assay. Treatment with recombinant p45-sErbB3 alone did not have an effect on the invasiveness of PC-3 or C4-2B cells (data not shown), suggesting that the invasion-stimulatory factor(s) is from p45-sErbB3-conditioned medium. Invasiveness of LNCaP cells in this assay was low to undetectable and was not enhanced by treatment with p45-sErbB3–conditioned medium (Fig. 1D).

Identification of p45-sErbB3-induced factors from mouse calvaria

Conditioned media from calvaria cultures contain many secretory proteins, some of which may be enhanced by treatment with p45-sErbB3 and act to stimulate prostate cancer cell invasiveness. To identify such factors, we purified total RNA from the calvaria treated or not treated with p45-sErbB3 and used microarray analysis to profile the expression of skeletal-related genes in response to the p45-sErbB3 treatment. Results showed that the expression of osteonectin (also known as SPARC, the secreted protein, acidic and rich in cysteine), biglycan, and type I collagen, was increased by exposure to p45-sErbB3 (Fig. 2A). To validate these findings, we used northern blotting with RNA prepared from calvaria treated or not treated with p45-sErbB3. We found that p45-sErbB3 treatment led to a 1.6-fold (1.6 ± 0.2, n=3) increase in osteonectin mRNA; a 2.4-fold (2.4 ± 0.5) increase in type I collagen; and a 1.9-fold (1.9 ± 0.2) increase in biglycan (Fig. 2B).

Fig. 2
p45-sErbB3 stimulates expression of osteonectin and other osteoblast genes in mouse calvaria. A, analysis of an osteogenic gene array showed the increased expression of osteonectin (Osn), biglycan (Bgn), and type I collagen (Col-1) in response to p45-sErbB3 ...

Of the three calvarial proteins increased by p45-sErbB3, osteonectin is known to promote prostate cancer cell migration and invasion (12, 13). Thus, the enhanced invasiveness of prostate cancer cells by p45-sErbB3 may be mediated, at least in part, by osteonectin produced by bone. To evaluate osteonectin protein levels in the conditioned medium of calvarial cultures, we used western blotting and confirmed the elevated expression of osteonectin by calvaria treated with p45-sErbB3 (as compared with control calvaria) at day 4 after treatment (Fig. 2C).

Osteonectin increases prostate cancer cell invasiveness

Next, we examined whether osteonectin has a direct effect on prostate cancer cell invasiveness by measuring the effect of recombinant osteonectin on LNCaP, C4-2, and PC-3 cell invasion. Purified osteonectin protein promoted the invasiveness of PC-3 cells and that of C4-2B cells, but not that of LNCaP cells, in a concentration-dependent manner in the transwell assay, suggesting that osteonectin alone is sufficient to stimulate the invasiveness of PC-3 cells (Fig. 3A). However, osteonectin did not affect the proliferation of any of the three cell lines (data not shown).

Fig. 3
Osteonectin mediates the effect of p45-sErbB3 on the invasiveness of prostate cancer cells. A, In Boyden transwell assays with the indicated osteonectin concentrations, cells that had migrated to the outside of the upper chamber after a 20-h incubation ...

Neutralization of osteonectin results in inhibition of p45-sErbB3–induced prostate cancer cell invasiveness

To further examine our observation that the conditioned medium of calvaria treated with p45-sErbB3 enhances the invasiveness of PC-3 and C4-2B cells is due to osteonectin, we used two different neutralizing antibodies against osteonectin to block its function in the invasion assay. These antibodies, a polyclonal and a monoclonal IgG, but not a control antibody, significantly reduced the invasion of PC-3 cells exposed to p45-sErbB3-conditioned medium (Fig. 3B), suggesting that p45-sErbB3 enhances the invasiveness of these cells via osteonectin.

Collectively, we have shown that p45-sErbB3 has an osteoblastic effect on bone and stimulates the expression of osteonectin, which enhances prostate cancer cell invasiveness (Fig. 3C). In addition to osteonectin, other factors (such as biglycan or type I collagen) are probably also involved in this process; nevertheless, the increase in osteonectin might be one of the pathophysiological responses to p45-sErbB3 that contribute to prostate cancer bone metastasis.

Discussion

Advanced prostate carcinoma is often associated with bone metastases. The mechanisms responsible for the organ-specific metastasis of this form of cancer are not known. In our quest to identify factors that mediate the bidirectional interactions between prostate cancer cells and the bone microenvironment, we demonstrate here that p45-sErbB3 stimulates bone to secrete osteonectin, which subsequently enhances the invasiveness of bone-tropic prostate cancer cells. Although mouse calvaria was used in this study, we consider that our observations are likely to be translatable to human bone. Mouse model has been widely used in addressing both developmental and disease-related aspects of human bone biology and most of the known human mutations that cause abnormal bone density, remodeling and mineralization have resulted in similar phenotypes in mice. Both mouse and human osteoblasts originate from the mesenchyme and respond similarly to various stimuli in vitro. In addition, human osteonectin peptide sequence is 92% identical to mouse osteonectin. Thus, our study warrants further investigation of the correlation of p45-sErbB3 and osteonectin in clinical specimens of the bone metastasis of prostate cancer.

Osteonectin is a major noncollagenous glycoprotein originally identified in bovine bone (14, 15). Osteonectin is important in bone formation; osteonectin-null mice exhibit profound osteopenia due to decreases in the numbers and surface areas of osteoblasts and osteoclasts (16). Osteonectin may also be involved in the progression of prostate cancer to bone-metastatic disease (17). Jacob et al. (12) demonstrated that osteonectin promoted the invasiveness of bone-metastasizing cancer cells including PC-3. Similarly, De et al. (13) reported that osteonectin increases prostate cancer cell invasiveness by interacting with the cell-surface receptors αvβ3 and αvβ5. The functional activity of αvβ3 and αvβ5 integrins is higher on the bone-metastasizing C4-2B cells than on the lymph node-metastasizing LNCaP cells, despite the similar expression levels of these two integrins in C4-2B and LNCaP. In the study reported here, we showed that p45-sErbB3 stimulates osteonectin secretion from bone, which increased the invasiveness of prostate cancer cells PC3 and C4-2B. These observations are consistent with the conclusion that osteonectin is an osteoblastic factor that could selectively interact with the bone-tropic cancer cells and enhance their invasiveness.

The mechanism by which osteonectin increased the invasiveness of PC-3 cells and the C4-2B cells in our study is not clear. Jacob et al. (12) showed that treating PC-3 cells with osteonectin increased the activity of matrix metalloprotease (MMP) -2 in PC-3 cells and that this increased activity may lead to increased tumor cell invasiveness. MMPs are a group of proteinases that degrade collagens, elastin, and other components of the extracellular matrix. To see whether p45-sErbB3 would increase the expression of MMPs by PC-3 cells, we examined MMP-2 and MMP-9 activity in medium from PC-3 cells that were treated or not treated with conditioned medium from calvaria treated with p45-sErbB3. In contrast to the report by Jacob et al. (12), we did not detect significant differences in MMP-2 or MMP-9 activity in these PC-3 cells by zymography (data not shown). Whether other MMPs or matrix degrading enzymes are involved in the invasion activity seen in our study is not known.

Other bone extracellular matrix proteins, such as osteopontin and bone sialoprotein, have also been reported to contribute to the survival and growth of prostate cancer cells in bone. Osteopontin assists in cell adhesion, migration, and survival (18). Overexpression of osteopontin in LNCaP and PC-3 cells has been shown to increase the invasion of those prostate cancer cells (19). Bone sialoprotein facilitates the attachment of cancer cells to the bone and enhances the metastatic potential of cancer cells (20). In our study, we found that osteonectin stimulated the invasiveness of C4-2B cells, but neutralizing antibodies against osteonectin could not inhibit the invasiveness of C4-2B cells in response to conditioned medium from p45-sErbB3–treated calvaria (data not shown), suggesting that other invasion-enhancing factors are present in the conditioned medium. Whether biglycan, type I collagen, or both are responsible for differences in prostate cancer cell invasiveness awaits further investigation.

Acknowledgments

We thank Christine Wogan of the Department of Scientific Publications at M. D. Anderson Cancer Center for editing this manuscript. This work was supported by grants from the National Institutes of Health (CA111479, P50 CA90270, GM40711, and DK53176), the Charlotte Geyer Foundation, the Prostate Cancer Foundation, and the U.S. Department of Defense (PC061279).

Footnotes

Disclosure

The authors declare no conflicts of interest in connection with this manuscript.

References

1. Tu SM, Lin SH. Clinical Aspects of Bone Metastases in Prostate Cancer. In: Keller ET, Chung LW, editors. The Biology of Bone Metastases. Boston, MA.: Kluwer Academic Publishers; 2004. pp. 23–46.
2. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64:9209–16. [PubMed]
3. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LWK. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implication for bidirectional tumorstromal cell interaction in prostate carcinoma growth and metastasis. J Urol. 1992;147:1151–9. [PubMed]
4. Chung LWK. Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation. Semin Cancer Biol. 1993;4:183–92. [PubMed]
5. Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer. 2003;97:772–8. [PubMed]
6. Logothetis C, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nature Reviews Cancer. 2005;5:21–8.
7. Yang J, Fizazi K, Peleg S, et al. Prostate cancer cells induce osteoblast differentiation through a cbfa1-dependent pathway. Cancer Res. 2001;61:5652–9. [PubMed]
8. Vakar-Lopez F, Cheng CJ, Kim J, et al. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol. 2004;203:688–95. [PubMed]
9. Liang AK, Liu J, Mao SA, Siu VS, Lee YC, Lin SH. Expression of recombinant MDA-BF-1 with a kinase recognition site and a 7-histidine tag for receptor binding and purification. Protein Expr Purif. 2005;44:58–64. [PubMed]
10. Bradshaw AD, Bassuk JA, Francki A, Sage EH. Expression and purification of recombinant human SPARC produced by baculovirus. Mol Cell Biol Res Commun. 2000;3(6):345–51. [PubMed]
11. Sweetwyne MT, Brekken RA, Workman G, et al. Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies. J Histochem Cytochem. 2004;52(6):723–33. [PubMed]
12. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 1999;59:4453–7. [PubMed]
13. De S, Chen J, Narizhneva NV, et al. Molecular pathway for cancer metastasis to bone. J Biol Chem. 2003;278:39044–50. [PMC free article] [PubMed]
14. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981;26:99–105. [PubMed]
15. Sage H, Johnson C, Bornstein P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem. 1984;259:3993–4007. [PubMed]
16. Delany AM, Amling M, Priemel M, Howe C, Baron R, Canalis E. Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest. 2000;105:915–23. [PMC free article] [PubMed]
17. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 2000;6:1140–9. [PubMed]
18. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol. 2001;41:723–49. [PubMed]
19. Khodavirdi AC, Song Z, Yang S, et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res. 2006;66:883–8. [PubMed]
20. Zhang JH, Tang J, Wang J, et al. Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol. 2003;23:1043–8. [PubMed]